|
|
| |
|
| |
|
| |  | | | | | Can-Fite Biopharm Ltd. | | | | | Can-Fite has developed a breakthrough technology platform that is based on a novel proprietary scientific mechanism associated with multiple diseases including cancer, myeloprotection, arthritis and other diseases. The company’s first lead compound, CF101, has the potential to become the gold standard of cancer therapy: an oral, non-toxic chemotherapy drug that eliminates neutropenia. Can-Fite’s technology is based on the usage of drugs that bind and interact with adenosine receptors and activate a particular signal transduction pathway. The company identified an agonist that specifically suppresses cancer growth while at the same time promotes the growth of white blood cells and prevents neutropenia. To date, Can-Fite has solidified a substantial intellectual property position with nine patents filed, a few of which have already been granted. |
 |
|
|
|
|
|
| |
 |
| |
|
| |
 |
|
Status: Second round |
|
|
| |
 |
|
Fund III |
|
|
| |
 |
|
Email
Can-Fite Biopharm Ltd. |
|
|
| |
 |
|
10 Bareket St.
PO Box 7537
Petach Tikva
49170 |
|
|
| |
 |
|
+972-3-924 1114 |
|
|
| |
 |
|
+972-3-924 9378 |
|
|
| |
 |
|
Ilan Cohn,
CEO |
|
|
| |
 |
|
Founded 1998 |
|
|
|
